Pfizer, Aventis Still See Wiggle Room On FDA-Mandated Switches

FDA likely will face a legal challenge regardless of whether the agency decides to implement mandated Rx-to-OTC switches or chooses a more indirect policy yielding similar results, according to comments made by Aventis and Pfizer executives